Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 59Neoplasms 52Colorectal Neoplasms 27Carcinoma, Non-Small-Cell Lung 23Prostatic Neoplasms 21Lung Neoplasms 18Leukemia, Myeloid, Acute 16Recurrence 15Multiple Myeloma 12Stomach Neoplasms 11Melanoma 11Brain Neoplasms 11Ovarian Neoplasms 10Neoplasm Metastasis 10Motor Activity 10Head and Neck Neoplasms 10Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pancreatic Neoplasms 9Lymphoma, Non-Hodgkin 9Glioma 9Carcinoma, Renal Cell 9Myelodysplastic Syndromes 7Lymphoma 7Esophageal Neoplasms 7Colonic Neoplasms 7Carcinoma, Hepatocellular 7Lymphoma, Large B-Cell, Diffuse 6Leukemia 6

Interventions

dalpiciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HR+/HER2- Advanced Breast Cancer × 30 days × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡